Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

ISSN： 1551-7853

Source： European Diabetes Nursing, Vol.10, Iss.1, 2013-03, pp. : 31-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

By Holst Jens Juul

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 1, 2004-05 ,pp. : 155-166

Informa Healthcare

Access to resources Recommend Favorite

A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes

By Montanya Eduard

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1451-1467

Informa Healthcare

Access to resources Recommend Favorite

GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations

By Jespersen Maria J Knop Filip K Christensen Mikkel

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 1, 2013-01 ,pp. : 17-29

Informa Healthcare

Access to resources Recommend Favorite

GLP-1 agonists: a new approach for type 2 diabetes

Inpharma, Vol. 1, Iss. 1407, 2003-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Novel GLP-1 receptor agonists for diabetes

By Garber Alan J

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 1, 2012-01 ,pp. : 45-57

Informa Healthcare

Access to resources Recommend Favorite